This cohort contains serial WES alterations from patient samples collected as part of NCT02954536, a phase 2 evaluation of chemotherapy with trastuzumab and pembrolizumab in advanced/unresectable or m
The HER pathway is the driving force behind 30% of human breast cancers. It is important to understand how targeted therapies block different cellular pathways, and mechanisms of escape from this bloc
